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Abstract: Background and Objectives: Codeine requires biotransformation by the CYP2D6 enzyme,
encoded by the polymorphic CYP2D6 gene, to morphine for therapeutic efficacy. CYP2D6 phenotypes
of poor, intermediate, and ultra-rapid metabolisers are at risk of codeine non-response and adverse
drug reactions due to altered CYP2D6 function. The aim of this study was to determine whether
genotype, inferred phenotype, and urinary and oral fluid codeine O-demethylation metabolites could
predict codeine non-response following a short course of codeine. Materials and Methods: There
were 131 Caucasians with persistent pain enrolled. Baseline assessments were recorded, prohibited
medications ceased, and DNA sampling completed before commencing codeine 30 mg QDS for 5 days.
Day 4 urine samples were collected 1–2 h post morning dose for codeine O-demethylation metabolites
analysis. Final pain assessments were conducted on day 5. Results: None of the poor, intermediate,
ultra-rapid metabolisers and only 24.5% of normal metabolisers responded to codeine. A simple
scoring system to predict analgesic response from day 4 urinary metabolites was devised with
overall prediction success of 79% (sensitivity 0.8, specificity 0.78) for morphine and 79% (sensitivity
0.76, specificity 0.83) for morphine:creatinine ratio. Conclusions: In conclusion, this study provides
tentative evidence that day 4 urinary codeine O-demethylation metabolites could predict non-response
following a short course of codeine and could be utilised in the clinical assessment of codeine response
at the point of care to improve analgesic efficacy and safety in codeine therapy. We offer a scoring
system to predict codeine response from urinary morphine and urinary morphine:creatinine ratio
collected on the morning of day 4 of codeine 30 mg QDS, but this requires validation before it could
be considered for use to assess codeine response in clinical practice.
Keywords: pain; analgesics; cytochrome P-450 CYP2D6; chronic pain; codeine; pharmacogenetics;
pain management
1. Introduction
Prescriptions for codeine-based drugs increased by 10.5 percent between 2011 and 2012 in U.K.
primary care settings, with an associated net increase in drug ingredient costs of £10.3 million [1].
Codeine requires biotransformation to active metabolites (morphine) via the enzyme CYP2D6. Genetic
polymorphism of the CYP2D6 gene influences the activity of the CYP2D6 enzyme resulting in
inter-patient variability that may pose a risk of toxicity and sub-optimal analgesic response [2–17].
The phenotypic groups of CYP2D6 activity are poor metabolisers (PM, minimal or no CYP2D6 activity);
intermediate metabolisers (IM, reduced CYP2D6 activity); normal metabolisers (NM, normal CYP2D6
activity); and ultra-rapid metabolisers (UM, greater than expected CYP2D6 activity) [18–20].
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PM and IM phenotypes are at risk of sub-optimal analgesic response to codeine due to lower than
expected plasma concentrations of morphine. UM phenotypes are at risk of adverse drug reactions
(e.g., respiratory depression) due to higher than expected concentrations of morphine. The prevalence
in Caucasian adults is ~5–10% for PMs, ~2–11% for IMs, ~77–92% for NMs and ~2–11% for UMs [21].
Prevalence of UMs in North Africans, Ethiopians, and Arabs may be as high as 40% [22,23]. There does
not appear to be differences in the prevalence of CYP2D6 polymorphisms in pain patients and the
general population [24].
Combining codeine with a drug that inhibits CYP2D6 can change the phenotype of an individual
(i.e., phenocopying) due to competition for enzyme activity. For example, an NM may appear to be
an IM or a PM due to inhibition of CYP2D6 by the confounding drug [25,26]. Knowledge about the
magnitude of CYP2D6 inhibition for certain drugs aids prescribing [27–29]. Prescribing guidelines for
CYP2D6 phenotypes have been published with recommendations that PM, IM, and UM phenotypes
should be prescribed alternatives to codeine, tramadol, oxycodone, and nortriptyline [21,30,31]. The
benefits of tailoring prescribing decisions to CYP2D6 phenotype has been demonstrated [9,14,32–36].
However, CYP2D6 screening is not part of current clinical practice. We previously reported that
19.9% of patients referred by primary care physicians to a secondary care specialist pain management
clinic were at risk of drug interactions associated with co-prescription of analgesic prodrugs reliant
on CYP2D6 and CYP2D6 inhibitors [37]. A method of inferring phenotype without the need for
genotyping is needed at the point of care.
Accuracy of clinical CYP2D6 phenotyping has been explored using non-analgesic CYP2D6
prodrug drugs as urinary biomarkers of CYP2D6 phenotype. These drugs are not suitable to determine
CYP2D6 phenotype in pain patients. Tramadol would be an unsuitable CYP2D6 phenotyping agent
due to its strong opioid classification. Kirchheiner et al., [38] found that the ratio of urinary total
codeine:total morphine from a 0–6 h urine sample post 30 mg codeine dose correlated to PM, NM, and
UM phenotypes in healthy volunteers, although the study did not include any participants who were
IM phenotypes.
The aim of our study was to determine whether genotype, inferred phenotype and urinary and
oral codeine O-demethylation metabolites could predict codeine non-response in Caucasians with
persistent pain following a short course of oral codeine.
2. Materials and Methods
The objectives of the study were to: (I) determine the CYP2D6 genetic profile of codeine
non-response in self-reported Caucasians with persistent pain; (II) determine whether codeine
non-responsiveness differs between nociceptive and neuropathic pain states; and (III) determine
whether urinary and oral codeine O-demethylation metabolites predicted phenotype and
codeine response.
2.1. Study Design
A single site, population study for a clinical trial of a medicinal product (CTIMP) was designed
(http://www.legislation.gov.uk/uksi/2004/1031/pdfs/uksi_20041031_en.pdf). The primary endpoint was
codeine non-response defined as participants who did not display a reduction in pain scores of≥30% for
‘average pain during the previous 24 h’ over a course of regular codeine therapy. In addition, CYP2D6
genotype, urinary codeine O-demethylation metabolites, clinical response to codeine, and patient
reported outcomes—including brief pain inventory and global impression of health—were recorded.
The study protocol was reviewed by the research team at Seacroft Hospital, Leeds Teaching
Hospitals NHS Trust, Leeds U.K. and by two independent pain researchers. Study sponsorship was
granted by the Research and Development department and by the Quality Assurance team at Leeds
Teaching Hospitals NHS Trust. Ethical approval was granted by the Leeds East (Type 2, CTIMP flagged)
Research Ethics Committee (REC: 08/H1307/132). The study was authorised by the U.K. Medicines and
Healthcare Regulatory Agency, adopted by the National Institute of Health Research Clinical Research
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Network portfolio (UKCRN, ID 7230), and registered on the International Standard of Randomised
Controlled Trials database (ISRCTN; Trial identification number: 16874724). Amendments to study
design made after the commencement of the study were approved by the Research Ethics Committee
and the Medicines and Healthcare Regulatory Agency. The amendments included addition of a poster
advert to aid recruitment, removal of oral fluid testing following interim analysis and change to
inclusion criteria to include ‘worst pain’ in 24 h pain score.
2.2. Recruitment and Selection of Participants
A sample of 131 self-reported Caucasian persistent non-malignant pain patients were recruited
from the Pain Clinic at Seacroft Hospital, Leeds, U.K. from October 2009 to June 2014. Potential
participants were identified from the patient database held by pain service or directly from clinic by
their consultant. The research nurse (S.R.) searched the database for patients with pain of moderate
severity that had persisted for at least six months and who were suitable for the prescription of World
Health Organisation (WHO) step 2 analgesics such as codeine. Patients with uncontrolled or escalating
pain were not eligible for inclusion in the study. Each potential participant was sent a letter of invitation,
a participant information pack, and a consent form. They were contacted by telephone by the research
nurse (S.R.) 5–7 days later to discuss willingness and suitability to participate in the study.
2.3. Procedure
Potential participants were invited to attend the pain research clinic at the hospital on three
separate occasions within a 15-day period. Visit one involved consent, screening for eligibility,
enrolment and analgesic washout; visit two involved collection of samples for CYP2D6 genotyping,
analysis of urinary codeine O-demethylation metabolites and commencement of codeine treatment;
and visit three involved cessation of codeine treatment and measurement of study endpoints.
2.3.1. Study Visit One
Potential participants attended the pain clinic for approximately 1 h. The visit commenced
with a briefing about the study and taking signed informed consent prior to any trial procedures
being conducted.
Screening for Eligibility
Participants were interviewed by the pain research nurse (S.R.) or the principal investigator (H.R.)
to assess eligibility for study participation. Participants completed the modified Brief Pain Inventory
short form (BPI-sf) [39] to screen for pain severity and interference. The BPI-sf has two validated
elements for analysis: pain severity and pain interference. Pain severity is calculated as the mean
of scores (on a 0–10 numerical rating scale) for the items ‘pain at its worst in the last 24 h’, ‘pain at
its least in the last 24 h’, ‘pain on the average’, and ‘pain right now’. Pain interference reflects how
pain interferes with daily activities and is calculated as the mean of the items documenting how much
pain interfered with ‘general activity’, ‘mood’, ‘walking ability’, ‘normal work’, ‘relations with others’,
‘sleep and enjoyment of life’.
Inclusion criteria were: self-reported Caucasian; aged between 18–80 years; pain persisting greater
than 3 months as diagnosed by a pain physician and recorded on the patient database; and worst pain
in the last 24 h ≥4 points on question 3 of the BPI-sf (0 = No pain, 10 = Pain as bad as you can imagine;
i.e., moderate to severe pain).
Exclusion criteria were: known sensitivity to codeine, history of experiencing intolerable side
effects to opioids, persistent pain adequately controlled by weak opioids, history of recreational drug
or alcohol abuse within the last two years, surgery, radiotherapy, chemotherapy, or nerve blocks
less than four weeks prior to the study, pregnancy or lactation, significant anxiety or depression.
Participants were excluded if they were unable to complete questionnaires in English, had participated
in another clinical study within the previous four weeks, had been prescribed strong opioids that could
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interfere with urinalysis and who were unable to cease taking their medication for the study period.
Females who were less than two years post-menopausal who were not taking adequate contraceptive
precautions (i.e., an oral contraceptive, an approved hormonal implant, an intrauterine device or
condoms/diaphragm and spermicide) or who had not undergone hysterectomy or surgical sterilisation
(bilateral tubal ligation or bilateral oophorectomy) were excluded.
Procedures were undertaken to ensure there were no underlying medical conditions that required
further investigation. A 20 mL venous blood sample was collected and analysed. Participants were
excluded if they had inadequate renal function (i.e., serum creatinine as ≥130 µmol/L (females);
≥150 µmol/L (males)), liver enzymes aspartate aminotransferase or alanine aminotransferase more
than twice the upper limit of normal, alkaline phosphatase more than twice the upper limit of normal,
bilirubin outside of normal range, haemoglobin concentration outside normal limits, white blood
cell count below the lower limit of normal or above 12 × 109/L, and abnormal plasma electrolytes.
A urine sample was collected in a plain sterile container for dipstick analysis for pH, specific gravity,
leukocytes, nitrates, protein, glucose, ketones, urobilinogen, bilirubin, and blood using Combur Test®
(Roche Diagnostics, Risch-Rotkreuz, Switzerland) reactive strips. Participants with abnormal results
were discussed with the pain consultant (K.H.S.) to ensure that the participant was safe to continue on
the study, otherwise they were excluded. Females of childbearing potential were required to have a
negative urine pregnancy test.
Participants also completed a self-report version of the Leeds Assessment of Neuropathic Pain
Scale (S-LANSS) [40] to indicate the presence of neuropathic components of pain. A cut-point of ≥12
points on the S-LANSS was used to define the presence of neuropathic components of pain.
Analgesic Washout
At visit one, participants were asked to stop taking analgesic prodrugs requiring CYP2D6
biotransformation (codeine phosphate including combination therapies, tramadol) and CYP2D6
inhibitors identified using information from Baxter [28], Flockhart [29], and the Medicines and
Healthcare Regulatory Authority [41]. Participants were allowed to continue with prescribed
anti-depressants, anti-convulsants or non-steroidal anti-inflammatory drugs (NSAIDs) providing the
treatment was initiated at least two weeks prior to visit one and remained at a stable dose for the study
duration. Participants were allowed to continue with oral contraceptives that are a weak CYP2D6
inhibitor, and this was documented for analysis purposes.
All concomitant medication and any changes therein were recorded in the case report (data
collection) form. Participants were asked not to commence any new drug therapy throughout
the codeine treatment period (between visit two and visit three). Participants were dispensed
64 paracetamol tablets (500 mg) for breakthrough pain and instructed to take 1 g 4–6 hourly (maximum
of 4 g in 24 h) for pain relief if required throughout the study period. Participants were asked to
complete the BPI-sf and to document paracetamol consumption and any associated adverse events
every day in a pain diary before retiring to bed.
2.3.2. Study Visit Two
Visit two took place 48 h after visit one and lasted approximately 3 h. On arrival eligibility to
continue with the study was checked (i.e., results from blood and urine tests) and they completed the
BPI-sf which was used as pre-treatment baseline measure of pain severity and interference.
CYP2D6 Genotyping
CYP2D6 genotyping was performed to determine activity scores from which phenotype was
inferred. A 2 mL saliva sample was collected for CYP2D6 genotyping after a 30-min oral fast.
A Oragene•DNA Self-Collection all-in-one system (DNA Genotek, Ottawa, ON, Canada) was used for
the collection, preservation, transportation, and purification of DNA from saliva. Samples were stored
for no more than 6 months in the pain clinic at room temperature and protected from light (storage
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stability approximately 5 years: https://www.dnagenotek.com/ROW/pdf/PD-WP-005.pdf). Samples
were transported ambient in batches to KBiosciences Laboratory, Hertfordshire UK for DNA extraction
and processing. CYP2D6 allele selection and base sequencing for identification was determined from
allele frequencies for a Caucasian population from the literature [18,42]. A Kompetitive Allele Specific
PCR genotyping system (KASP™) was used for DNA extraction and processing (competitive allele
specific polymerase chain reaction) for CYP2D6 alleles *1, *2, *3, *4, *5, *6, *9, *10, *41 and a Hybeacon
assay for CYP2D6 duplication.
The genetic data was received electronically on encrypted Excel spreadsheets from the
KBiosciences Laboratory and transcribed—including deletions, duplications, and multiple SNPs/allele
identification—into a study specific worksheet designed to facilitate the process of inferring phenotype
from genotype (by H.R.). Alleles were allocated a CYP2D6 activity score using a scoring method by
Gaedigk et al. (1999) [43]. Phenotype was inferred from the total sum of activity scores of both alleles
and duplications using classifications reported by Crews et al. [44]. Worksheets were quality checked
and countersigned (by K.H.S.) to ensure correct phenotype had been inferred from genotype.
Collection and Analysis of Urinary Codeine O-demethylation Metabolites
A urine sample was obtained for analysis of urinary codeine O-demethylation metabolites to
confirm that no codeine had been consumed during the analgesic washout phase (i.e., at baseline).
In addition, participants were instructed to collect a sample of urine in sterile a universal container
1–2 h after the morning dose of codeine on the last day of treatment to store the sample in a cool
location until they returned to clinic the following day for study visit three. This sample was used
to analyse urinary codeine O-demethylation metabolites when the participant was equilibrated with
codeine. Samples were stored in the pain clinic at −20 ◦C until transported in batches to laboratories
at Leeds Teaching Hospitals NHS Trust. All samples were stored frozen at −10 to −35 ◦C until
analysis. Total urine morphine and codeine were quantified using liquid chromatography tandem
mass spectroscopy (LC-MS/MS). Gradient reversed phase liquid chromatography was performed
using a Shimadzu Prominence HPLC system (Shimadzu, Tokyo, Japan) fitted with a Thermo Hy-Purity
C8 column (Thermo Fisher Scientific, Cheshire, UK). Drugs were detected using an ABSciex API
5000 tandem mass spectrometer (ABSciex, Warrington, UK). Quantitation was achieved using the
internal standard peak area ratio method. The assay was calibrated using reference materials and
deuterated internal standards purchased from LGC (Teddington, UK). All urine samples were treated
with β-glucuronidase to hydrolyse glucuronide compounds prior to analysis to ensure that total
morphine concentration was measured. The lower limit of morphine quantification was 50 µg/L. Lower
limit of morphine detection was 10 µg/L. Results below the limit of quantification were provided with
the understanding the degree of uncertainty would be high (CV >20%). Samples that contained an
amount of morphine greater than the top calibration standard (500 µg/L) were diluted with deionised
water and re-analysed. Urine creatinine was measured by either a Beckman LX20 automated analyser
(Beckmann, High Wycombe, UK) using an alkaline picrate method or a Siemens Advia automated
analyser (Siemens, Surrey, UK) using an enzymatic method. Morphine:creatinine ratios were calculated
(µg morphine per mmol creatinine) to correct for differences in urine concentration.
Codeine Treatment
Codeine Phosphate tablets (30 mg, manufactured by TEVA U.K. Ltd. (Manufacturers Authorisation:
PL0289/506IR), Phoenix Healthcare Distribution) were procured by the pharmacy department of Leeds
Teaching Hospitals NHS Trust and stored protected from light below 25 ◦C. Participants received
28 tablets of 30 mg codeine phosphate (blister pack) and were instructed to take one 30 mg tablet
orally every four hours to a maximum of four tablets in 24 h. This would guarantee that participants
had completed three consecutive days of full dosing to ensure the participant was equilibrated with
codeine when they provided their urine sample 1–2 h after the morning dose of codeine on the last day
of treatment. Eight extra tablets were provided in the blister pack in case of loss or delayed clinic visit.
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Participants were administered their first dose of 30 mg codeine with 200 mL of water in the clinic
(dosing day 0).
Collection and Analysis of Oral Fluid O-demethylation Codeine Metabolites
Participants provided an oral fluid sample in clinic two hours after their first dose of codeine using
an Intercept® collection pad (Orasure Tech Inc, Bethlehem, PA, USA). The collection pad was placed
between the lower cheek and gums and gently rubbed back and forth along the gum line until the pad
was moist. Once moist the collection pad was left in the mouth for 2 min and then removed and placed
into a specimen vial containing 15% methanol in 4 mL ammonium acetate. Oral fluid samples were
frozen and stored at −20 ◦C. Samples were transported in batches to laboratories at Leeds Teaching
Hospitals NHS Trust for analysis of free codeine, morphine, norcodeine, and glucuronides of morphine
and codeine. Analysis of oral fluid in the first 20 participants identified only one sample as positive
for codeine metabolites. Following discussions with the laboratory undertaking the analysis, it was
concluded this method was unsuitable to be used to infer CYP2D6 phenotype post codeine dosing.
No further analysis was conducted and oral fluid sampling was removed from the study design.
At the end of study visit two, participants were issued with a pain diary to complete each day
before retiring to bed. Participants were telephoned by the research nurse (S.R.) on the day before visit
three so that adverse events could be assessed and to remind participants to collect their urine sample
to bring to clinic.
2.3.3. Study Visit Three
During visit three, participants returned their pain diary and completed the BPI-sf and the Patient
Global Impression of Change in Health. The assessors (S.R. and H.R.) completed the Clinician Global
Impression of Change Scale after reviewing the participant’s pain diary and any adverse events
reported by the participant during the visit. The Patient Global Impression of Change questionnaire
reflects the patient’s belief about treatment efficacy by rating change as ‘very much improved’, ‘much
improved’, ‘minimally improved’, ‘no change’, ‘minimally worse’, ‘much worse’, or ‘very much worse’.
Participants were asked to return all unused study medication and empty blister packs for drug
accountability and controlled destruction. Participants recommenced their regular analgesia or were
prescribed codeine if their pain has been effectively controlled at the end of the study period. All study
participants were followed up by telephone seven days later to ascertain any late adverse events.
2.4. Withdrawal of Participants from Study
Participants could withdraw from study at any time and without reason. It was planned that
data would be collected up until the time of withdrawal and used for analysis with the consent of the
participant. The investigator could to withdraw participants from the study at any time due to adverse
events, violation of the study protocol, lack of efficacy, or loss to follow-up.
2.5. Pharmacovigilance and Reporting of Adverse Events
Adverse events were captured verbally through any contact with participants or in pain diaries.
Serious adverse events were events resulting in death, a life-threatening situation, hospitalisation,
or significant disability or incapacity. Adverse events were defined as any untoward medical occurrence
observed in a participant during or following administration of codeine that did not necessarily have a
causal relationship with treatment. Adverse events could include unfavourable and unintended signs
and symptoms including abnormal laboratory findings that may or may not have a causal relationship
with the use of codeine or paracetamol. Adverse events were recorded and assessed, and the clinical
course of the adverse event was followed until resolution, stabilisation, or until it was determined that
the study treatment or participation was not the cause. Adverse events were categorised according
whether they were (‘expected’) or were not (‘unexpected’) listed on the codeine phosphate 30 mg
“Summary of Product Characteristics” [45].
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2.6. Outcome Measures
The primary endpoint in this study was codeine non-response defined as a participant who had
<30% reduction in BPI-sf pain ‘on the average’ at the end of the course of codeine therapy. This was
measured as the difference between pain ‘on the average’ at pre-codeine baseline (study visit two)
and the mean of pain ‘on the average’ during codeine therapy (day 0 to day 4). Secondary endpoints
used in this study were CYP2D6 genotype, measurements of urinary codeine O-demethylation
metabolites, patient reported outcomes (BPI-sf, Patient Global Impression of Change to Health)
assessor determined outcomes (Clinician Global Impression of Change to Health) and frequency and
severity of adverse events.
2.7. Data Management and Analysis
The protocol of statistical analyses and calculation of sample size a priori were developed
with the biomedical statistical department from Napp Pharmaceuticals. The statistical protocol was
peer reviewed by the biomedical statistics department from the University of Leeds as part of the
Research Ethics Committee and Medicines and Healthcare Regulatory Agency approval process.
The development of the database and statistical analysis of recorded data reported was undertaken by
the principal investigator (H.R.). All statistical analyses were performed using IBM SPSS Statistics 21.
2.7.1. Sample Size Calculation
It was calculated that a sample size of 121 participants would give 90% power to detect a larger
proportion of codeine non-responders than the null hypothesis of 10%, assuming the true proportion is
20%, using a 5% significance level for a one-sided test. Therefore, a recruitment target of 150 was set
based on a drop-out rate of 20% to obtain 121 evaluable participants.
2.7.2. Statistical Analysis
The population for analysis was defined as (I) participants who attended the screening visit
(enrolled population) and (II) participants who had their codeine response determined and their
CYP2D6 phenotype inferred from genotype (intention-to-treat population).
2.7.3. Analysis of Primary Outcomes
The proportion of codeine non-responders (primary outcome) was calculated with 95% confidence
intervals using the exact binomial distribution. A logistic regression analysis was conducted
to predict codeine non-response (dependent variable, dichotomous data) from CYP2D6 activity
score (independent variable, ordinal data). Analysis of variance (ANOVA) was used to compare
log-transformed levels of urinary codeine O-demethylation metabolites between CYP2D6 phenotypes.
Logistic regression was used to predict analgesic response using log-transformed urinary total morphine
and morphine:creatinine ratio as covariates. A multivariate logistic regression model was developed
to predict analgesic response using activity score and log-transformed urinary total morphine and
morphine:creatinine ratio. The suitability of the model as predictor of analgesic response was assessed
using receiver operating characteristic (ROC) curves.
2.7.4. Analysis of Secondary Outcomes
A descriptive analysis of data from BPI-sf, S-LANSS and Global Impression of Change was
performed against codeine non-response and CYP2D6 phenotype. In this study, we used ‘pain on the
average’, ‘pain severity’, and ‘pain interference’ in our statistical analysis of BPI-sf outcomes. Concurrent
medication was analysed to determine if CYP2D6 substrates impacted on codeine response through
autophenocopying. The type and number of substrates was tabulated against CYP2D6 phenotype
and codeine response status and a logistic regression analysis used to determine whether CYP2D6
substrates predicted analgesic response. CYP2D6 substrate classification was determined through
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bioinformatics and cheminformatics databases for each drug identified [46,47]. Study medication
(codeine 30 mg QDS and paracetamol 1 g PRN) was excluded from the analysis.
3. Results
3.1. Characteristics of the Sample Population at Enrolment
A total of 131 participants (age range = 23–79 years, 79 females: 52 males) were enrolled into the
study (enrolled population, Figure 1). One male participant withdrew consent following visit one
without giving a reason. Three females withdrew from the study due to adverse events. One female
(NM phenotype, CYP2D6 activity score 2) withdrew due to moderate rash and difficulty in breathing but
also experienced multiple mild adverse events such as nausea, loss of appetite, diarrhoea, restlessness,
and disturbed sleep. The other females withdrew due to stomach cramps and disturbed sleep (NM
phenotype, CYP2D6 activity score 2) and excessive belching and increased acid reflux (PM phenotype,
CYP2D6 activity score 0). The CYP2D6 genotype of two females could not be determined and
they were unable to provide an additional DNA sample for analysis. Thus, 125 participants (age
range = 23–78 years, 74 females: 51 males) had their codeine response determined and their CYP2D6
phenotype inferred from genotype (Table 1).
Table 1. Characteristics of the study from the intention to treat analysis (n = 125) participants at
pre-codeine baseline day 0.
Variable
ITT Group
Male Female Total
Number (%) 51 (40.8%) 74 (59.2%) 125 (100%)
Age (minimum–maximum) 27–78 years 23–77 years 23–79 years
Age (Mean ± SD) 57.10 ± 12.33 55.64 ± 14.74 56.26 ± 13.71
Mean ± SD BPI-sf
Pain severity 5.73 ± 1.61 6.25 ± 1.82 6.09 ± 1.75
Pain interference 4.99 ± 2.68 5.05 ± 2.59 5.02 ± 2.51
Pain ‘on the average’ 5.46 ± 1.95 5.81 ± 2.21 6.31 ± 1.76
Tally (%) S-LANSS
≥12—Neuropathic pain 18/51 (35.30%) 35/74 (47.30%) 53/125 (42.74%)
<12—Nociceptive pain 33/51 (64.70%) 39/74 (52.71%) 71/125 (57.26%)
Medication at enrolment
Prescribed CYP2D6 analgesic prodrug 29/51(56.86%) 44/74(59.46%) 73/125(58.4%)
Tally (%) Phenotype
PM (Activity Score = 0.0) 4/51 (7.84%) 7/74 (9.49%) 11/125 (8.8%)
IM (Activity Score = 0.5) 5/51 (9.80%) 1/74 (1.35%) 6/125 (4.8%)
NM (Activity Score = 1.0–2.0)
• NM (Activity Score = 1.0) 12/51 (23.53%) 20/74 (27.03%) 32/125 (25.6%)
• NM (Activity Score = 1.5) 9/51 (17.65%) 9/74 (12.16%) 18/125 (14.4%)
• NM (Activity Score = 2.0) 20/51 (39.22%) 36/74 (48.65%) 56/125 (44.8%)
UM (>2.0) 1/51 (1.96%) 1/74 (1.35%) 2/125 (1.6%)
ITT, Intention to treat; SD, Standard Deviation; BPI-sf, Brief Pain Inventory short form; NRS, Numerical Rating
Scale; S-LANSS, Self-report version of the Leeds Assessment of Neuropathic Pain Scale; PM, Poor metaboliser; IM,
Intermediate metaboliser; NM, Normal metaboliser; UM, Ultra metaboliser.
3.2. Characteristics of Pain at Enrolment (n = 131)
Data collected for withdrawn participants were included in the analysis of the enrolled group
but not the analysis of the ITT group. The mean ± SD duration of pain was 127.51 ± 133.50 months
(Median: 73 months, range 9–636 months), with majority of participants diagnosed with low back
pain. At enrolment 55/131 (42%) participants had a S-LANSS score ≥12 suggesting a predominantly
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neuropathic pain state; 76/131 (58%) participants had a S-LANSS score <12 suggesting a predominantly
nociceptive pain state.
At enrolment, 125/131 (95%) participants were taking at least one analgesic and/or pain adjuvant
(either prescribed or over-the-counter). There were 36/131 (27%) participants taking one analgesic or
pain adjuvant, 33/131 (25%) taking two, 30/131 (23%) taking three, 21/131 (16%) taking four, 2/131 (2%)
taking five, and 3/131 (2%) taking six. There were 77/131 (59%) participants taking an analgesic
prodrug that was reliant on CYP2D6 activity to obtain analgesic efficacy, with co-codamol (codeine
and paracetamol combined, 31/131 (24%) participants) and tramadol (26/131 (20%)) being the most
commonly prescribed. Only two (1.5%) participants were prescribed more than one CYP2D6 prodrug
analgesics concurrently (codeine with tramadol, and co-codamol with tramadol). There were 91/131
(70%) participants that reported they had previously failed to respond to one or more CYP2D6 analgesic
prodrugs (50/131 (38%) and 46/131 (35%) respectively), with failure to respond to tramadol being
the most commonly reported. There were 14/131 (11%) participants that reported failure to respond
to both tramadol and co-codamol and 4/131 (3%) reporting failure to respond to tramadol, codeine,
and co-codamol.
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3.3. CYP2D6 Genotyping and Inferred Phenotype at Enrolment
Two of the 131 saliva samples collected for CYP2D6 genotyping were discarded because it was
not possible to confirm the CYP2D6 activity score. In one sample, it was not possible to classify the
CYP2D6 phenotype due to undetermined allele duplication indicating UM if present or NM if absent.
In the other sample, it was not possible to determine the presence of the reduced functional allele
*41. Phenotype was inferred from 129 of the 131 enrolled participants as follows: PM = 12/129 (9%),
IM = 6/129 (5%), NM = 109/129 (85%), and UM = 2/129 (2%). The proportion of these phenotypes was
within the rang estimated in a general Cauca ian population by Crews et al. [21]. The majority of the
NM phenotype group (59/129, 46%) possessed full CYP2D6 activity (activity score of 2.0), with 32/129
(25%) having an activity score of 1.0, and 18/129 (14%) having an activity score of 1.5. The most common
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diplotype was CYP2D6*1/*2 (NM activity score of 2), followed by the fully functional CYP2D6*1/*1
(NM activity score of 2), CYP2D6*1/*4 (NM activity score of 1) and CYP2D6*4xN/*4 (PM activity
score of 0).
A risk of suboptimal response to codeine is likely for PM, IM, or UM phenotypes. The number of
participants from the enrolled sample that were taking prodrugs reliant on CYP2D6 activity were 10/12
(83%) PMs, 4/6 (67%) IMs, and 1/2 (50%) UMs. The number of participants from the enrolled sample
that reported they had failed to respond to prodrug analgesic medication in the past were 9/10 (90%)
PMs, 3/6 (50%) IMs, and 1/2 (50%) UMs.
3.4. Analysis of CYP2D6 Phenotype and Analgesic Response to Codeine
There were statistically significant reductions in ‘pain severity’, ‘pain interference’, and ‘pain on
the average’, between pre-codeine baseline and the end of codeine treatment when measured as the
difference between pain ‘on the average’ at pre-codeine baseline (study visit two) and the mean of pain
‘on the average’ during codeine therapy (i.e., day 0 to day 4, Table 2). However, responder analysis
revealed that 99/125 (79%) participants that did not achieve a clinically meaningful reduction of pain of
≥30% from baseline and these participants were categorised as codeine non-responders (41/51 (80%)
males, 58/74 (78%) females).
Table 2. Mean ± SD BPI-sf scores in the ITT population (n = 125).
BPI-sf
Visit 1
Pre-Analgesic
Washout
Visit 2
Pre-Codeine
Baseline Day 0
End of
Dosing Day
(Day 0)
End of
Day 1
End of
Day 2
End of
Day 3
End of
Day 4
Mean Day
0–4
Pain
severity
(composite)
6.31 ± 1.76 6.09 ± 1.75 5.93 ± 1.99 5.67 ± 2.27 5.54 ± 2.28 5.57 ± 2.40 5.62 ± 2.45 5.67±2.17 *
Pain
interference
(composite)
5.02 ± 2.51 6.14 ± 2.11 5.31 ± 2.40 5.09 ± 2.58 4.90 ± 2.59 4.91 ± 2.66 4.91 ± 2.73 5.02 ± 2.51 *
Pain ‘on the
average’ 6.09 ± 1.75 6.31 ± 1.76 6.00 ± 1.94 5.68 ± 2.28 5.55 ± 2.24 5.51 ± 2.37 5.57 ± 2.35 5.66 ± 2.11 *
The pain severity score was calculated as the mean of NRS scores for ‘worst’, ‘least’, ‘average’ and ‘right now’ pain.
The pain interference score was calculated as the mean of seven items of pain interference. * p < 0.05 indicating
statistical significance between mean day 0–4 and pre-codeine. SD, Standard Deviation; BPI-sf, Brief Pain Inventory
short form; ITT, Intention to treat; NRS, Numerical Rating Scale.
There were 53/125 (42%) participants with a S-LANSS score ≥12 suggesting a predominantly
neuropathic pain state; 72/125 (58%) participants had a S-LANSS score <12 suggesting a predominantly
nociceptive pain state. There were 26/124 (21.0%) participants categorised as codeine responders
(i.e., ≥30% reduction of pain) of which 10/26 (39%) had an S-LANSS score <12. Thus, 43/98 (44%)
of participants with an S-LANSS score <12 did not respond to codeine. There were no significant
differences in the frequency of response between participants categorised as having predominantly
neuropathic or nociceptive pain states (z = 0.496, p = 0.62, odds ratio = 1.25 (95% CI: 0.52, 3.03)).
All PMs, IMs, and UMs were categorised as codeine non-responders (19 of 125 (15%) participants)
and were negatively binomial distributed suggesting that these phenotypes would not respond to
codeine in the general population (Table 3). There were 106/125 (83%) participants categorised as NMs.
There were 80/106 NMs (76%) categorised as codeine non-responders. Of these, 39/56 (70%) NMs with
activity scores of 2 (two fully functional alleles) were categorised as codeine non-responders, 14/18
(78%) with activity scores of 1.5 were categorised as codeine non-responders and 27/32 (84%) with
activity scores of 1 were categorised as codeine non-responders.
The logistic regression analysis found that CYP2D6 activity score made a significant contribution
to the prediction of codeine response (Beta = 0.963, Wald = 5.67 p = 0.017). The model Chi-square
indicated that CYP2D6 activity score affected codeine response (Chi-sq = 6.78, df = 1, p = 0.009).
The odds ratio (95% confidence interval) was 2.62 (1.186–5.790) suggesting that individuals with a high
CYP2D6 activity score were 2.62 times more likely to respond to codeine than individuals with a low
CYP2D6 activity score.
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Table 3. Urinary codeine O-demethylation metabolites according to CYP2D6 activity score (AS) and
codeine response.
Sample PM(AS 0.0)
IM
(AS 0.5)
NM
(AS 1.0–2.0)
NM
(AS 1.0)
NM
(AS 1.5)
NM
(AS 2.0)
UM
(>2.0)
Total number
(% non-response
within phenotype)
11
(100%)
6
(100%)
96
(83.33%)
32
(84.38%)
18
(77.78%)
56
(69.64%)
2
(100%)
Codeine Responders 0 0 26 5 4 17 0
Codeine
non-responders 11 6 80 27 14 39 2
Mean ± SD total
morphine (µg/L)
Codeine responders
no
responders
identified
no
responders
identified
2902.65 ±
2504.43
1754.6 ±
1661.56
2523.75 ±
1634.72
3329.47 ±
2822.71
no
responders
identified
Codeine
non-responders # 44.18 ± 39.66
415.16 ±
317.83
2419.77 ±
2106.61
1444.65 ±
1342.90
2925.43 ±
2410.52
2846.08 ±
2226.72
5330.00 ±
3464.82
Mean ± SD
morphine:creatinine
ratio (µg/L)
Codeine responders
no
responders
identified
no
responders
identified
420.04 ±
346.91
271.80 ±
228.06
347.00 ±
243.93
480.82 ±
389.56
no
responders
identified
Codeine
non-responders # 6.91 ± 4.46 35.83 ± 7.14
311.94 ±
231.47
197.96 ±
150.23
307.00 ±
177.35
389.69 ±
263.18 646.50 ± 12.02
# one sample missing from NM (AS 1.0), n = 26 not 27. SD, Standard Deviation; PM, Poor metaboliser; IM,
Intermediate metaboliser; NM, Normal metaboliser; UM, Ultra metaboliser.
3.5. CYP2D6 Phenotype and Global Impression of Change
Analysis of the Patient Global Impression of Change to Health found that 20/26 (77%) participants
who obtained an analgesic response to codeine reported improvement on the global impression of
change questionnaire and 70/99 (71%) participants who did not obtain an analgesic response to codeine
reported improvement on the global impression of change questionnaire. All PMs, IMs, and UMs failed
to obtain an analgesic response yet 9/11 (82%) PMs reported improvement, 2/6 (33%) IMs reported
improvement and 1/2 (50%) UMs reported improvement. Of the NMs who did not obtain an analgesic
response 58/80 (73%) reported improvement compared with 20/26 (77%) of participants who did obtain
an analgesic response. The Clinician Global Impression of Change to Health was compared with
the self-reported Patient Global Impression of Change to Health for accuracy and was successfully
matched in 72% of the participants.
3.6. Analysis of Adverse Events
There were no reported serious adverse events during the course of the study. The most
common ‘expected’ adverse events were headache (46/125 (37%) participants), nausea (41/125 (33%)
participants), and constipation (37/125 (30%) participants), with the majority of ‘expected’ adverse
events reported by codeine non-responders. The most common ‘unexpected’ adverse events were
diarrhoea (13/125 (10%) participants), stomach cramps (11/125 (9%) participants), and flu-like symptoms
(11/125 participants (8%)), with a majority of ‘unexpected’ adverse events reported by codeine
non-responders. Separate logistic regression analyses of each of these adverse events (i.e. headache,
constipation, dry mouth, nausea, and drowsiness) with CYP2D6 activity score and responder status
were not statistically significant.
3.7. Analysis of CYP2D6 Autophenocopying
Concurrent medication was analysed to determine if CYP2D6 substrates impacted on codeine
response through autophenocopying. There were 41/125 (33%) participants not taking CYP2D6
substrates, 47 (38%) taking one CYP2D6 substrate, 23 (18%) taking two CYP2D6 substrates, 10 (8%)
taking three CYP2D6 substrates, and 4 (3%) taking four CYP2D6 substrates. Logistic regression analysis
found that the number of concurrent CYP2D6 substrates and log urinary transformed total morphine
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did not make a significant contribution to the prediction of codeine response (number CYP2D6
substrates Beta = 0.08, Wald = 0.16, p = 0.69; urinary transformed total morphine Beta = 0.000155,
Wald = 2.829208, p = 0.09).
3.8. Analysis of Urinary Codeine O-demethylation Metabolites
Urine samples were collected before the first dose of codeine on study visit two (pre-codeine
baseline day 0) and after the first dose of codeine on day 4. The sample of one participant was discarded
due to leakage in transit from the clinic to the laboratory. Thus, 124 samples were analysed for codeine
O-demethylation metabolites (Table 3). Day 4 data for each participant categorised as responder or
non-responder for each CYP2D6 phenotype/activity are shown in Figures 2–5.
Data for urinary total morphine were log transformed using a base −10 logarithm to reduce skew.
One urine sample from day 4 of a participant categorised as a PM was negative for urinary total morphine
metabolites (<50 µg/L) and was not included in the log transformed calculation. Log transformed data
was categorised according to CYP2D6 phenotype and analgesic response. There were no significant
effects of responder status in the different categories of activity score for NM phenotypes (activity
score = 1, F(1,29) = 0.12, p = 0.73: activity score = 1.5, F(1,16) = 0.59, p = 0.45: activity score = 2,
F(1,54) = 6.64E-10, p = 1.0). There were similar findings for morphine:creatinine ratio calculated to correct
for levels of hydration. One-way ANOVA on log transformed morphine:creatinine ratio found significant
effects between CYP2D6 activity scores (F(5,117) = 38.43, p < 0.001). There were no significant effects
of responder status in the different categories of activity score for NM phenotypes (activity score = 1,
F(1,28) = 0.03, p= 0.87: activity score = 1.5, F(1,16) = 0.24, p= 0.63: activity score = 2, F(1,54) = 0.43, p= 0.51).
Logistic regression analysis found that log transformed total morphine and morphine:creatinine ratio did
not make a significant contribution to the prediction of codeine response (total morphine Beta = −0.54,
Wald = 0.415, p = 0.52; morphine:creatinine ratio Beta = 1.50, Wald = 2.60, p = 0.11).
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Figure 5. Individual value plot of day 4 urinary morphine:creatinine ratio for each CYP2D6
phenotype/activity score of participants defined as codeine responders (≥30% reduction in mean
day 0–day 4 ‘average pain’ 0–10 numerical rating scale (NRS) score when compared to baseline). AS,
Activity Score; NM, Normal metaboliser.
3.9. Predicting Analgesic Response from Codeine Urinary Metabolites
We devised a simple scoring system in an attempt to predict analgesic response to codeine
(≥30% relief) for urinary total morphine ranges and morphine:creatinine ratio for different CYP2D6
activity scores based on detected urinary metabolite (Table 4) whereby;
• 0 points = Unl kel to respond to codeine (activity sco e = 0 (PM) and activity score = 0.5
(IM), expected urinary total morphine <500 µg/L, expected urinary morphine:creatinine
ratio = 0–100 µg/mmol);
• 1 point = Uncertain whether will respond to codeine (activity score = 1.0 (NM), expected urinary
total morphine = 500–1499 µg/L, expected urinary morphine:creatinine ratio = 101–250 µg/mmol)
• 2 points = Likely to respond to codeine (activity score = 1.5 or 2.0 (NM), expected urinary total
morphin = 1500–7500 µg/L, expected urinary morphine:creatinine ratio = 251–1000 µg/mmol)
• 3 points = U certain whether will respond to codeine and potential for adverse events (activity score
>2.0 (UM), expected urinary total morphine >7500 µg/L, expected urinary morphine:creatinine
ratio >1000 µg/mmol).
A multivariate logistic regression analysis was used to determine whether log-transformed mean
urinary total morphine for day 4 could predict analgesic response and a ROC curve used to assess the
suitability of the model. The test of the full model against a constant only model was significant at
p < 0.05 for pr i ting codein responder status using urinary total morphin for day 4 (Beta = 2.64,
Wald = 35.46, p < 0.001). The model chi-square good ess of fit w s significant (chi-sq. = 43.47, df
= 1, p < 0.001). Overall prediction success was 79% with an 82% prediction success for expected
codeine non-response and 75% prediction success for expected codeine response, with a sensitivity 0.8,
specificity 0.78. Mean urinary morphine:creatinine ratio for day 4 the test of the full model against a
constant only model was significant at p < 0.05 for predicting codeine responder status (Beta = 2.77,
Wald = 34.42, p < 0.001). The model chi-square goodness of fit was significant (chi-sq. = 44.46, df = 1,
p < 0.001). Overall prediction success was 79% with an 88% prediction success for expected codeine
non-response and 68% prediction success for expected codeine response, with a sensitivity of 0.76, and
specificity of 0.83.
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Table 4. Points system for predicting codeine response from day 4 urinary total morphine metabolites (µg/L) based on detected urinary metabolite.
CYP2D6 Activity
Score (AS)
CYP2D6
Phenotype
Codeine
Non-Responder Codeine Responder
Suggested Range for
Predicting Codeine
Response
Expected Codeine
Response Points Rationale
Mean total morphine
(µg/L)
Mean total morphine
(µg/L)
Mean total morphine
(µg/L)
0 PM 44.2 no respondersidentified 0–499
Probably will not
respond to codeine 0 Includes PM and IM phenotypes
0.5 IM 415.2 no respondersidentified 0–499
Probably will not
respond to codeine 0 Includes PM and IM phenotypes
1 NM 1444.7 1754.6 500–1499 May not respond tocodeine 1
Includes NM AS 1 phenotype or individuals
CYP2D6 phenocopying
1.5 NM 2925.4 2523 1500–7500 Should respond tocodeine 2
Includes NM AS 1.5 and AS 2 phenotypes:
Expected to respond to codeine
2 NM 2846.1 3329.5 1500–7500 Should respond tocodeine 2
Includes NM AS 1.5 and AS 2 phenotypes:
Expected to respond to codeine
3 UM 5330 no respondersidentified >7500
May not respond and
potential ADRs 3 Includes UM phenotypes: Potential for ADRS
Mean morphine:
creatinine ratio
(µg/mmol)
Mean morphine:
creatinine ratio
(µg/mmol)
Mean morphine:
creatinine ratio
(µg/mmol)
0 PM 6.91 no respondersidentified 0–100
Probably will not
respond to codeine 0 Includes PM and IM phenotypes
0.5 IM 35.83 no respondersidentified 0–100
Probably will not
respond to codeine 0 Includes PM and IM phenotypes
1 NM 197.96 271.8 101–250 May not respond tocodeine 1
Includes NM AS 1 phenotype or individuals
CYP2D6 phenocopying
1.5 NM 307 347 251–1000 Should respond tocodeine 2
Includes NM AS 1.5 and AS 2 phenotypes:
Expected to respond to codeine
2 NM 389.69 480.82 251–1000 Should respond tocodeine 2
Includes NM AS 1.5 and AS 2 phenotypes:
Expected to respond to codeine
3 UM 646.5 no respondersidentified >1000
May not respond and
potential ADRs 3 Includes UM phenotypes: Potential for ADRs
PM, Poor metaboliser; IM, Intermediate metaboliser; NM, Normal metaboliser; UM, Ultra metaboliser; AS, Activity score; ADR, Adverse drug reaction.
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3.10. Predicting CYP2D6 Activity Score from Codeine Urinary Metabolites
We devised a simple scoring system in an attempt to predict CYP2D6 activity score from urinary
total morphine and morphine:creatinine ratio based on detected urinary metabolite (Table 5) whereby;
• 0 points = activity score = 0 (PM), expected urinary total morphine = 0–150 µg/L, expected urinary
morphine:creatinine ratio ≤20 µg/mmol);
• 0.5 points = activity score = 0.5 (IM), expected urinary total morphine 151–500 µg/L, expected
urinary morphine:creatinine ratio = 21–100 µg/mmol);
• 1 point = activity score = 1.0 (NM), expected urinary total morphine = 501–2000 µg/L, expected
urinary morphine:creatinine ratio = 101–300 µg/mmol)
• 1.5 points = activity score = 1.5 (NM), expected urinary total morphine = 2001–3000 µg/L, expected
urinary morphine:creatinine ratio = 301–375 µg/mmol)
• 2.0 points = activity score = 2.0 (NM), expected urinary total morphine = 3001–7500 µg/L, expected
urinary morphine:creatinine ratio = 376–600 µg/mmol)
• 3.0 points = activity score >2.0 (UM), expected urinary total morphine >7501 µg/L, expected
urinary morphine:creatinine ratio >601 µg/mmol).
Table 5. Points system for predicting for predicting CYP2D6 activity score from day 4 urinary
total morphine metabolites (µg/L) and morphine:creatinine ratio (µg/mmol) based on detected
urinary metabolite.
CYP2D6
Activity Score
(AS)
CYP2D6
Phenotype
Codeine
Non-Responder
Codeine
Responder
Suggested Range for
Predicting CYP2D6
Activity Score
Points Rationale
Mean total
morphine
(µg/L)
Mean total
morphine
(µg/L)
Mean total morphine
(µg/L)
0 PM 44.2 no respondersidentified 0–150 0
<300 µg/L is a negative
cut off point in codeine
drug screens [49]
0.5 IM 415.2 no respondersidentified 151–500 0.5
Severely reduced
function and comparable
to PMs [50]
1 NM 1444.7 1754.6 501–2000 1
Expected to respond to
codeine
1.5 NM 2925.4 2523 2001–3000 1.5
2 NM 2846.1 3329.5 3001–7500 2
3 UM 5330 no respondersidentified >7501 3 Potential for ADRs
Mean morphine:
creatinine ratio
(µg/L)
Mean morphine:
creatinine ratio
(µg/L)
Morphine: creatinine
ratio (µg/L)
0 PM 6.91 no respondersidentified ≤20 0
<300 µg/L is classed as a
negative cut off point in
codeine drug screens [49]
0.5 IM 35.83 no respondersidentified 21–100 0.5
Severely reduced
function and comparable
to PMs [50]
1 NM 197.96 271.8 101–300 1 Expected to respond tocodeine
1.5 NM 307 347 301–375 1.5
2 NM 389.69 480.82 376–600 2
3 UM 646.5 no respondersidentified >601 3 Potential for ADRs
PM, Poor metaboliser; IM, Intermediate metaboliser; NM, Normal metaboliser; UM, Ultra metaboliser; AS, Activity
score; ADR, Adverse drug reaction.
A multivariate logistic regression analysis was used to determine whether log-transformed urinary
total morphine could predict CYP2D6 activity score and a ROC curve used to assess the suitability of
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the model. Urinary total morphine and urinary Morphine:Creatinine ratio at day 4 did not make a
significant contribution to the prediction of CYP2D6 activity score.
4. Discussion
This study found that 79% of participants did not achieve a clinically significant reduction of
pain of ≥30% four days after commencement of codeine 30 mg QDS. The proportion of phenotypes
in the sample were within the range estimated for adult Caucasians [21], with 46% of NMs having a
CYP2D6 activity score of 2.0 reflecting full CYP2D6 activity. None of the PMs, IMs, and UMs, and
only 24.5% of NMs responded to codeine. CYP2D6 activity score made a significant contribution to
the prediction of codeine response with high CYP2D6 activity scores being 2.62 times more likely to
respond than low CYP2D6 activity scores. The number of concurrent CYP2D6 substrates and urinary
morphine did not make a significant contribution to the prediction of codeine response. We devised a
simple scoring system to predict analgesic response (≥30% relief) from day four urinary metabolites
and found that this had overall prediction success of 79% (sensitivity 0.8, specificity 0.78) for morphine
and 79% (sensitivity 0.76, specificity 0.83) for morphine:creatinine ratio.
At enrolment, 59% of our sample had been prescribed analgesics dependent on CYP2D6 activity
such as co-codamol and tramadol, a similar percentage to a recent service improvement project that
reviewed prescribing information provided by general practitioners (GP) for new referrals to a UK
National Health Service hospital pain clinic [37]. Prescribers are advised to review medication within
2–4 weeks after titration to identify patients that are unlikely to respond [51], although in our sample
70% of participants reported that they had previously failed to respond to one or more CYP2D6
analgesics despite still consuming such medication. Our study found no differences in the number
of adverse events (mostly headache, dry mouth, nausea, drowsiness, and constipation) between
phenotype and/or activity score. Literature on the incidence of adverse events associated with different
phenotypes is sparse and contradictory [52–55].
In our responder analysis, 79% participants did not achieve a clinically meaningful reduction of pain
of ≥30% to codeine 30 mg QDS, based on the cut-point for response consistent with current guidelines
from Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) [56,57].
Analysis of pre-post change in mean ‘pain severity’, ‘pain interference’, and ‘pain on the average’
of the BPI-sf found statistically significant improvements, although the use of mean data can be
misleading because between-group averages may hide proportions of participants that may have
responded very well, or extremely poorly to the drug [58]. This is supported by evidence from studies
of pharmacological interventions that have found that pain outcomes have U-shaped distributions with
some participants experiencing substantial reductions in pain and some minimal improvement [59–62].
We found that 43% (42/97) of non-responders scored ≥12 on S-LANSS in line with evidence suggesting
that neuropathic pain is less likely to respond to codeine than predominantly nociceptive or mixed
pain [63]. None of the PMs, IMs, or UMs responded to codeine 30mg QDS [15,17,23], although we
recognise that groups samples were small with only two UMs. If the parent drug (codeine and
tramadol) must be biotransformed to an active metabolite for therapeutic effect, then UM phenotypes
are at risk of experiencing adverse drug reactions from high levels of the active metabolite, with IM and
PM phenotypes experiencing no therapeutic effects [15,17,23]. Evidence suggests that UM phenotypes
suffer lack of efficacy due to rapid metabolism whereas PM phenotypes suffer from complications from
higher than desired plasma concentrations of the drug [64,65]. Ultra-rapid formation of morphine
would only short-term analgesia that is not maintained for 4–6 h and would pose a risk of toxicity in
UMs [23]. Therefore, codeine is not an appropriate drug for long term analgesia for persistent pain.
It is also possible that a disproportionately high number of treatment resistant participants in
the sample was a consequence of polypharmacy. Participants were allowed to maintain concurrent
prescribed medication during the study period providing medication was not a CYP2D6 inhibitor
(excluding oral contraceptives) to prevent phenocopying through enzyme inhibition. However, five
participants were taking CYP2D6 inhibitors with up to a 50% reduction in enzyme activity and all were
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NMs and codeine non-responders. Three of these participants (activity score = 2) were prescribed
oral contraceptives, one (activity score = 2) was prescribed diltiazem (weak inhibitor, [27]), and one
(activity score = 1) was self-administrating over-the-counter diphenhydramine (Benadryl®, moderate
inhibitor [29]). It is likely that CYP2D6 phenocopying occurred in these participants resulting in NMs
with CYP2D6 activity scores of 2 presenting as activity scores of 1, and those with activity scores of 1
presenting with activity scores of 0.5 (i.e., as IMs). In addition, three NMs were taking strong CYP2D6
inhibitors (paroxetine or fluoxetine) of which two (activity score = 1.5 and activity score = 2) were
codeine non-responders. These individuals down-titrated these CYP2D6 inhibitors so that they had
ceased taking the drug three days before the baseline visit, although it is possible that this wash out
period was insufficient for systemic clearance of these drugs and their metabolites.
There is debate about the combination of CYP2D6 alleles and level of CYP2D6 activity that
constitutes the IM phenotype. We used an activity score of 0.5 to infer IM phenotype in-line with
Clinical Pharmacogenetics Implementation Consortium guidelines (1 non-functional allele + 1 reduced
function allele: activity score = 0.5). The Dutch Pharmacogenetics Working Group recommend that IM
phenotype is inferred from an activity score of 0.5 or an activity score of 1 (fully functional allele +
non-functional allele or homozygous partially functional alleles) because of reduced enzyme function
compared with NM phenotypes with activity scores of 1.5 or 2 [30,31]. Commercially available CYP2D6
microarrays such as the Amplichip® infer IM phenotype from activity scores of 0.5 or 1 (homozygous
partially functional alleles) because of reduced enzyme function compared with NM phenotypes with
activity scores of 1, 1.5, or 2 [66–69]. If we had categorised IM using an activity score of 0.5–1.0 instead
of 0.5 then we would have observed codeine response in 13% participants rather than 0%. If NM
was categorised using an activity score of 1.5–2.0 we would have observed a codeine response in 28%
of participants rather than 24.5% of participants when categorised using activity scores 1.0–2.0. It is
reasonable from these findings to suggest that a CYP2D6 activity score of 1.0 should not be categorised
as an NM phenotype because codeine response was only achieved in a minority of participants.
However, an activity score of 1.0 should not be categorised IM because of increased CYP2D6 enzyme
activity and the possibility of responding to codeine compared with individuals with an activity score
of 0.5 who will not respond to codeine. Perhaps a new phenotype classification of moderate metaboliser
(MM) may be a more accurate description for an activity score of 1.0. The MM phenotype classification
would represent increased enzyme activity compared with the IM phenotype and reduced enzyme
activity compared with the NM phenotype.
One should be cautious when extrapolating our findings to the general pain population. The main
limitations of the study were the low sample of PM, IM, and UM participants and the poor analgesic
response rates in all groups. This impacts on the reliability of the predictive model. It was not possible
to enrich the cohort through additional recruitment in the present study, so we recommend that the
validity of our scoring system and predictive model is evaluated in a multi-centre study with larger
samples. The poor response rate is likely to be due to the fact that participants had been referred to a
specialist pain clinic because they were treatment resistant. Eighty individuals were excluded from
participation because they had previously experienced intolerable side effects to morphine, codeine,
co-codamol, or tramadol. Also, individuals may have declined to participate in the study because of
intolerable side effects to codeine in the past. We suspect that these exclusions would be UMs, IMs,
and PMs biasing our sample toward individuals with NM and MM phenotypes.
It was assumed that the duration of the wash-out period was sufficient to reduce potential
drug interactions with CYP2D6 inhibitors. Five participants continued to take CYP2D6 inhibitors
during codeine treatment and this may have reduced their responsiveness to codeine and affected
urinary measurements of codeine metabolites. Medication compliance was monitored by diary entries
and by counting returned medication/blister packaging at clinic visits and found to be 75–100%,
with 82% of the participants categorised as fully compliant. Nevertheless, it is possible that some
participants supplemented study medication with over-the-counter codeine at home that is likely to
elevate concentrations of codeine metabolites. Likewise, failure to collect urine samples at the time
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specified by the investigators (i.e., one to two hours after the morning codeine dose) would result in
lower than expected concentrations of codeine metabolites. A written reminder to the participant to
collect the day 4 urine sample was printed on the day 3 pain diary.
Another confounder was the selection of CYP2D6 alleles for the customised genotyping microarray
as participants may have CYP2D6 polymorphisms not included in the microarray or that are yet
to be discovered. In these individuals, the allele *1 (no polymorphisms detected) would have been
allocated indicating a fully functional allele. As scientific advancements in genotyping methodology
and knowledge about CYP2D6 polymorphisms are ongoing, it is recommended that investigators
consult the Human CYP2D6 Allele Nomenclature for an up to date overview of CYP2D6 alleles when
customising CYP2D6 microarrays [18].
5. Conclusions
This study provides tentative evidence that day 4 urinary codeine O-demethylation metabolites
could predict non-response following a short course of codeine and could be utilised in the clinical
assessment of codeine response at the point of care to improve analgesic efficacy and safety in
codeine therapy. We offer a scoring system to predict codeine response from urinary morphine and
urinary morphine:creatinine ratio collected on the morning of day 4 of codeine 30 mg QDS but this
requires validation before it could be considered for use to assess codeine response in clinical practice.
Translating CYP2D6 genotyping and/or phenotyping to clinical reality remains problematic. Whether
a urine test on day 4 has clinical utility is questionable as the response at this time-point is detectable
by patient self-report. Clearly, a pre-emptive urine test is desirable. Moreover, urinary concentrations
of morphine may be more useful than genotype when inferring phenotype in clinical practice. There
remains a need for higher standard pharmacogenomic education especially on CYP2D6 and pain
management in undergraduate and post-graduate education that is relevant to clinical practice for
all disciplines.
An adequately sized multi-centre study conducted in a primary care setting using samples from
the general population that includes CYP2D6 genotyping is needed to confirm our findings. Future
pharmacogenomic studies using codeine in persistent pain patient populations could offer genotyping
to participants who have declined to take part because of codeine intolerability. This would enable a
full analysis of the frequencies of CYP2D6 phenotypes. There is also a need for a multi-centre study
to validate the concentration range of codeine O-demethylation metabolites against activity scores.
We recommended that participants with a non-functional allele + fully functional allele (activity score
= 1) are analysed separately to those with homozygous partially functional alleles (activity score = 1)
to determine whether there is a difference between the metabolic capabilities of these individuals.
This would aid development of an accurate method to infer CYP2D6 phenotype in a clinical setting.
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